A recent clinical study published in the journal Gastroenterology Research and Practice showed that Stretta radiofrequency therapy has long-term efficacy, safety and durability in patients with gastroesophageal reflux disease (GERD) who are not doing well with proton pump inhibitors. Stretta (Mederi Therapy) utilizes low-power, low-temperature radiofrequency energy to reduce gastroesophageal reflux disease (GERD) symptoms by remodeling the lower esophageal sphincter. The mechanism of Stretta micro radiofrequency treatment for GERD may include: (1) Stretta micro radiofrequency treatment may relieve symptoms by causing localized esophageal nerve damage, thereby making the esophagus less sensitive to damage factors and deactivating the nerve endings in the lower esophageal sphincter. ②Increased muscle wall thickness at the gastroesophageal junction: Stretta microfrequency treatment resulted in a 50% increase in muscle wall thickness at the gastroesophageal junction. This single-center follow-up study evaluated the prognosis of GERD in 26 patients treated with Stretta who started treatment between June 2002 and March 2013 and had been followed for at least 8 years. 8-year follow-up results were compared with baseline data and the previous 4-year follow-up, including clinical evaluation, gastroscopy, esophageal pressure and pH-indicator studies. Patient prognosis was assessed according to heartburn and heartburn-related quality of life (HRQL) scores, and general quality of life (QoL) scores were determined by SF-36 survey, medication use, lowered esophageal sphincter pressure, and esophageal count exposure. At 4 years, a significant decrease in heartburn scores (mean, -2.8 points; 95% CI -1.8 to -3.6) and HRQL scores (mean, -14 points; 95% CI -10 to -21) was observed in patients who adhered to 8 years of follow-up (heartburn: mean, -1.8 points; 95% CI -1.4 to 2.2; HRQL: mean, -11 points; 95% CI -9 to – 14). QoL scores were significantly higher in all patients at 4 years (mean increase in mental SF-36, 13 points; 95% CI, 8 to 17; mean increase in physical SF-36, 12 points; 95% CI, 9 to 13) and at 8 years, mean increase in mental, 13 points; 95% CI, 9 to 15; mean increase in physical, 9 points; 95% CI, 6 to 11. In addition, in both follow-up periods, 80.7% and 76.9% of patients discontinued proton pump inhibitor therapy, respectively (P=0.0001 for both). One of the most striking results of the study was the “complete absence of any? Barrett’s esophagus or erosive esophagitis,” said Professor Luca Dughera (Health and Science Hospital, Turin, Italy) in a press release. “These findings clearly show that with good symptom control, Stretta reduces patients’ dependence on medication while also reducing the harmful effects of long-term esophageal acid exposure (a major ???? cause) from its harmful effects. ”The study adds to the growing body of long-term data …… Stretta has so far become the most studied non-surgical treatment for GERD,” expressed Professor Will Rutan (CEO of Mederi Therapeutics) in a press release.